The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Modeling amyloid beta and tau pathology in human cerebral organoids
Open accessAbstract
The typical abnormalities observed in the brain of Alzheimer's disease (AD) patients include synaptic alterations, neuronal death, brain inflammation, and the accumulation of protein aggregates in the form of amyloid plaques and neurofibrillary tangles. Despite the development of many animal and in vitro models for AD, there is a lack of an experimental approach that fully recapitulates essential aspects of the disease in human cells. Here, we report the generation of a new model to study AD, consisting of cerebral organoids (COs) produced from human-induced pluripotent stem cells (iPSCs). Under our experimental conditions, COs grow to form three-dimensional (3D) structures containing neural areas with cortical-like organization. Analysis of COs by histological and biochemical methods revealed that organoids produced from iPSCs derived from patients affected by familial AD or Down syndrome (DS) spontaneously develop over time pathological features of AD, including accumulation of structures highly reminiscent to amyloid plaques and neurofibrillary tangles. These pathological abnormalities were not observed in COs generated from various controls, including human iPSCs from healthy individuals, human iPSCs from patients affected by Creutzfeldt-Jakob disease, mouse embryonic stem cells (ESCs), or mouse iPSCs. These findings enable modeling genetic AD in a human cellular context in a 3D cortical-like tissue developed in vitro from patient-specific stem cells. This system provides a more relevant disease model compared to pre-existing methods and offers a new platform for discovery of novel targets and screening of drugs for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Despite this limitation, iPSC-based models derived from individuals with a MAPT mutation indicate molecular mechanisms underlying tauopathies (Gonzalez et al., 2018; lovino et al., 2015; Jiang et al., 2018; Nakamura et al., 2019; Silva et al., 2016, 2020; Wray, 2017).”
From ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids (2021) · cites this paper as Gonzalez et al., 2018
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The HNO model has been shown to recapitulate some of the key pathological features of AD and offers greater complexity and translational potential as compared to conventional cell and animal models92–95.”
From GRAMD1B is a regulator of lipid homeostasis, autophagic flux and phosphorylated tau (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Emerging roles of caspase-3 in apoptosis
Porter, A. G., & Jänicke, R. U. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400476 · Cited by 3,921
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931
Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure
Qian, X., Nguyen, H. N., Song, M. M., Hadiono, C., Ogden, S. C., Hammack, C., Yao, B., Hamersky, G. R., Jacob, F., Zhong, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.032 · Cited by 2,127
Generation of cerebral organoids from human pluripotent stem cells
Lancaster, M. A., & Knoblich, J. A. (2014) · Nature Protocols · doi:10.1038/nprot.2014.158 · Cited by 1,823
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195
Cited by
Sorted by citations
Items 401–432 of 432
Alzheimer’s Disease Brain Organoids as a Source of Disease-Relevant Amyloid-Beta OligomersPreprint
Zanderigo, E., Fatima, M., Becker, S., & O’Neil, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.09.710594
From mice to clinical relevance: humanizing neuroscience with human-based model systems
Bak, A., van Loo, K. M. J., Kronenberg‐Versteeg, D., & Koch, H. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1776439
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
Du génome humain au modèle murin : compréhension des ciliopathies
Delvallée, C. (2020) · theses.fr (ABES) · doi:10.70675/09e80c82z8902z406cz811az98cd7652a079
Hemonnot-Girard, A.-L. (2021) · theses.fr (ABES) · doi:10.70675/9c8a4775zd774z494ez9bbazf7566faefa8f
Boyd, R. J., Dong, D., Sagar, R., Iliuk, A. B., Ahmed, W., Androni, X., Porsteinsson, A. P., Rosenberg, P. B., Lyketsos, C. G., Witwer, K. W., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71273
Dakhel, A., Mothes, T., Eltom, K., Michno, W., & Erlandsson, A. (2026) · iScience · doi:10.1016/j.isci.2026.115819
Differential A-to-I editing of SINE B2 RNAs unveils an epitranscriptome response to Aβ neurotoxicity
Mitchell, L., Saville, L., Gollen, B., Haight, T., Roy, R., Turner, C., Cheng, Y., Kovalchuk, I., Mohajerani, M. H., & Zovoilis, A. (2026) · Life Science Alliance · doi:10.26508/lsa.202603668
Kang, H., Jang, B.-K., Yun, S., Jeong, H., Park, E., Oh, K.-I., Jeong, J., & Jeong, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135748
Patient cerebral organoids capture Alzheimer’s disease proteomic biomarkers and drug targetsPreprint
Thomson, S., Li, X. C., Walker, S., Tang, T. C. Y., Graham, M. E., Olechnowicz, S. W. Z., Bowden, R. J., Waugh, K. A., Slawson, C. M., Burns, J. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733874
Modeling Alzheimer’s disease with brain organoids: mechanisms, applications, and future directions
Zhao, Q., Li, S., Ju, Y., Kong, X., & Liu, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1791272
Angelovski, A., Hříbková, H., Sedmík, J., Liscakova, B., Švecová, O., Cesnarikova, S., Černá, K. A., Pospíšilová, V., Král, M., Kolajová, M., et al. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01779-7
Aubert, A., Comby, A.-C., Bramoulle, A., Mendoza-Ferri, M. G., Azzolin, P., Li, H., Moussy, A., Das, S., Colombo, B. M., & Mendoza-Parra, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.23.740401
López-León, C. F., Sala‐Jarque, J., del Rı́o, J. A., & Soriano, J. (2026) · Biomedicines · doi:10.3390/biomedicines14081670
Guruacharya, A., Härtung, T., dos Reis, R. S., Moreira, N. C. D. S., Attisano, L., Bolognin, S., Iqbal, K., & Rajbanshi, B. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.103051
Modeling Strategies for Neurodegenerative Diseases: In Vitro, In Vivo and In Silico Frameworks
Martorella, F., Cigolini, C., Pupo, G., Alberio, T., & Lualdi, M. (2026) · Biomedicines · doi:10.3390/biomedicines14102227
Bach, D., Hoang, V. H., & Nguyễn, T. L. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06193-0
Using Brain Organoids to Explore Human Neurobiology
Marei, H. E. S., & Hasan, A. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01808-5
Flemin, S. P. J., Vigneswaran, V., & Thiruthanigesan, K. (2026) · Moratuwa Engineering Research Conference (MERCon) · doi:10.1109/mercon71835.2026.11691312
From Primary Cells to Organoids: Expanding the Biological Relevance of In Vitro Cellular Models
Deng, F., Wang, Y., Castellano, L. A., & Zhao, C. (2026) · Cells · doi:10.3390/cells15191741
Amale, P. N., & Tiwari, D. H. (2026) · Alternatives to Laboratory Animals · doi:10.1177/02611929261492225
Kjar, A., Kim, H., Spetz, M. R., Jarrett, Z., Fernandez, M., Wang, J., Russotti, M. L., Bodnya, C., Chavarría, D., Hohman, T. J., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00376
Burdman, G., Hanna, M., Yndart, A., Vashist, A., & Lakshmana, M. K. (2026) · Cells · doi:10.3390/cells15191768
An age-preserving neuronal iSpheroid platform for modeling human aging and Alzheimer’s diseasePreprint
Alsolami, S., Wang, M., Sabedot, T. S., Singh, U., Kirk, B., Mitchell, L. E., Hernandez, M., Skvir, N. J., Bowman, C., Oiwa, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.30.755853
From Amyloid Exposure to Genetic Causality: Converging hiPSC-Based Models of Alzheimer’s Disease
Colasuonno, F., Valenza, A., Rossin, F., & Moreno, S. (2026) · Cells · doi:10.3390/cells15191793
Matta, C., Cheon, Y.-H., Vágó, J., Mészár, Z., Kim, E. H., Jiang, S., Balogh, A., Zana, M., Dinnyés, A., & Jin, E. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103752
Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging
Wang, S., Elia, L., Liu, W., & Finkbeiner, S. M. (2026) · Journal of Clinical Investigation · doi:10.1172/jci209602
Body-on-chip systems and clinical biomarkers discovery
Härtung, T., & Smirnova, L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-16110-0.00008-x
High-content imaging of live microglia-containing Alzheimer’s disease brain organoidsPreprint
Quang, D., Summers, R., Dooling, B. R., Esquer, H., Zhou, Q., LaBarbera, D. V., Vergara, M. N., Chial, H. J., Potter, H., & Johnson, N. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.26.761970
Developing precision nanoparticle-based drug delivery systems for Alzheimer's disease therapy
Shan, Q., Zheng, W., Yao, W., Bai, Y., Ding, W., Wang, J., & Bai, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103789
Metadata
- Authors
- Gonzalez, C., Armijo, E., Bravo-Alegria, J., Becerra-Calixto, A., Mays, C. E., & Soto, C.
- Affiliations
- Universidad de Los Andes, Chile (CL)
- Universidad de Antioquia (CO)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Soto, Claudio
- Venue
- Molecular Psychiatry
- Published
- 2018-08-31
- Volume
- 23
- Issue
- 12
- Pages
- 2363-2374
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC6594704
- OpenAlex
- W2889449128
- Cited by
- 430
- References
- 33
- Citations by year
- 2026: 43 · 2025: 55 · 2024: 63 · 2023: 60 · 2022: 56 · 2021: 78 · 2020: 48 · 2019: 24 · 2018: 2
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG061069)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, brain organoids, amyloid plaques, neurofibrillary tangles, tau pathology, amyloid-beta, induced pluripotent stem cells, familial Alzheimer's disease, Down syndrome, patient-specific disease modeling, drug screening
- MeSH terms
- Aged, Alzheimer Disease, Brain, Cerebral Cortex, Female, Humans, Infant, Male, Middle Aged, Neurons, Organoids, Phosphorylation, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Cell Culture Techniques, Induced Pluripotent Stem Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
